Symbiotech Pharmalab IPO: 35% Premium, Strong Investor Demand
By ThePip DeskSymbiotech Pharmalab IPO garners significant investor interest, with a Grey Market Premium of ₹350, suggesting a 35.43% listing premium. IPO details and subscription status.
Symbiotech Pharmalab Ltd’s IPO indicates significant investor interest, with an estimated listing price of ₹1,338, representing a 35.43% premium over its issue price.
The public offering, which launched on August 24, 2026, has already seen substantial subscription across key investor categories.
Key IPO Numbers
- Issue Size: ₹1,757 crore
- Price Band: ₹938 to ₹988 per share
- Lot Size: 15 shares
- Overall Subscription (as of August 25, 2026): 1.71 times
The Grey Market Premium (GMP) for Symbiotech Pharmalab Ltd IPO stands at ₹350 as of August 25, 2026.
This GMP suggests a listing at ₹1,338, though such premiums are speculative and do not guarantee actual listing performance.
Investor Subscription Breakdown
- Small Non-Institutional Investors (S-NII): 3.65 times
- Retail Investors: 2.00 times
- Qualified Institutional Buyers (QIB): 0.57 times
QIB demand was lower initially, but institutional bidding often increases closer to the closing date.
The IPO concludes on Thursday, August 27, 2026, with allotment expected on August 28, 2026, and listing on September 1, 2026.
The GMP saw an upward trend, peaking at ₹410 on August 22 before moderating to its current level.
Investors are advised to monitor final subscription data and broader market conditions as the IPO progresses.